Agonist-like pharmacotherapy for stimulant dependence: Preclinical, human laboratory, and clinical studies

Annals of the New York Academy of Sciences

Volumn 1187, Issue , 2010, Pages 76-100

  Herin, David V ^a   Rush, Craig R ^b,c   Grabowski, John ^a,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF MINNESOTA DULUTH   (United States)

Author keywords

Agonist; Amphetamine; Bupropion; Cocaine; Medication development; Methamphetamine; Modafinil; Stimulant abuse; Substitution; Treatment

Indexed keywords

AM 2517; AMFEBUTAMONE; AMPHETAMINE; BUPRENORPHINE; CARBIDOPA PLUS LEVODOPA; COCAINE; DEXAMPHETAMINE; DIAMORPHINE; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; FENFLURAMINE; FLUOXETINE; LISDEXAMFETAMINE; METHADONE; METHAMPHETAMINE; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; PHENTERMINE; PLACEBO; UNCLASSIFIED DRUG; VANOXERINE;

ANHEDONIA; ATTENTION DEFICIT DISORDER; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DEPENDENCE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; HALLUCINATION; HEROIN DEPENDENCE; HUMAN; INSOMNIA; MAINTENANCE DRUG DOSE; MENTAL DISEASE; NARCOLEPSY; NONHUMAN; PARANOIA; PRACTICE GUIDELINE; PREVALENCE; QUESTIONNAIRE; REVIEW; RISK REDUCTION; SCHIZOPHRENIFORM DISORDER; SELF REPORT; SIDE EFFECT; SOMNOLENCE; STEREOTYPY; SUBSTITUTION THERAPY; SYMPTOM; TREATMENT INDICATION; WITHDRAWAL SYNDROME;

EID: 77949282225     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05145.x     Document Type: Review

References (171)

1. Goodman, L.S.&A. Gilman. 1941. The Pharmacological Basis of Therapeutics. MacMillan. New York.
2. Rogers, A.E. et al. 1997. Compliance with stimulant medications in patients with narcolepsy. Sleep 20: 28-33.
3. Baberg, H.T., R.A. Nelesen & J.E. Dimsdale. 1996. Amphetamine use: return of an old scourge in a consultation psychiatry setting. Am. J. Psychiatry 153: 789-793.
4. Goldstein, A. 2001. Addiction: From Biology to Drug Policy. Oxford University Press.New York.
5. Musto, D.F. 1998. International traffic in coca through the early 20th century. Drug Alcohol Depend. 49: 145-156.
6. World Health Organization. 2004. Neuroscience of Psychoactive Substance Use and Dependence. WHO, Geneva, Switzerland.
7. SAMHSA. 2008. Results from the 2007 National Survey on Drug Use and Health. Rockville, MD.
8. SAMHSA. 2008. Treatment Episode Data Set (TEDS) Highlights-2006. Rockville, MD.
9. Afonso, L., T. Mohammad & D. Thatai. 2007. Crack whips the heart: a review of the cardiovascular toxicity of cocaine. Am. J. Cardiol. 100: 1040-1043.
10. Campbell, G.A. & M.H. Rosner. 2008. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. Clin. J. Am. Soc. Nephrol. 3: 1852-1860.
11. Droogmans, S. et al. 2007. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am. J. Cardiol. 100: 1442-1445.
12. Glauser, J. & J.R. Queen. 2007. An overview of noncardiac cocaine toxicity. J. Emerg. Med. 32: 181-186.
13. Karch, S.B. 2005.Cocaine cardiovascular toxicity. South Med. J. 98: 794-799.
14. Nzerue, C.M., K. Hewan-Lowe & L.J. Riley Jr. 2000. Cocaine and the kidney: a synthesis of pathophysiologic and clinical perspectives. Am. J. Kidney Dis. 35: 783-795.
15. Pozner, C.N., N. Levine & R. Zane. 2005. The cardiovascular effects of cocaine. J. Emerg. Med. 29: 173-178.
16. Knuepfer, M.M. 2003. Cardiovascular disorders associated with cocaine use: myths and truths. Pharmacol. Ther. 97: 181-222 (doi:10.1186/cc6166).
17. Devlin, R.J. & J.A. Henry. 2008. Clinical review: major consequences of illicit drug consumption. Crit. Care 12: 202.
18. Diercks,D.B. et al. 2008. Illicit stimulant use in aUnited States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module). Am. J. Cardiol. 102: 1216-1219.
19. Jovanovski,D., S. Erb&K.K.Zakzanis. 2005.Neurocognitive deficits in cocaine users: a quantitative review of the evidence. J. Clin. Exp. Neuropsychol. 27: 189-204.
20. Scott, J.C. et al. 2007. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol. Rev. 17: 275-297.
21. De Sola Llopis, S. et al. 2008. Cognitive performance in recreational ecstasy polydrug users: a two-year followup study. J. Psychopharmacol. 22: 498-510.
22. Bedi,G.&J.Redman. 2008. Ecstasy use and higher-level cognitive functions: weak effects of ecstasy after control for potential confounds. Psychol. Med. 38: 1319-1330.
23. Schilt, T. et al. 2008. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users. Psychol. Med. 38: 1309-1317.
24. Horner, M.D. 1999. Attentional functioning in abstinent cocaine abusers. Drug Alcohol Depend. 54: 19-33.
25. Post, R.M. 1975. Cocaine psychoses: a continuum model. Am. J. Psychiatry 132: 225-231.
26. Rounsaville, B.J. 2004. Treatment of cocaine dependence and depression. Biol. Psychiatry 56: 803-809.
27. Darke, S. et al. 2008. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 27: 253-262.
28. Jacobs, E. et al. 2008. An exploratory analysis of neurocognition in methamphetamine-induced psychotic disorder and paranoid schizophrenia. Cogn. Behav. Neurol. 21: 98-103.
29. McKetin, R. et al. 2008. Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants. Drug Alcohol Rev. 27: 277-285.
30. Vocci, F.J. & I.D. Montoya. 2009. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr. Opin. Psychiatry 22: 263-268.
31. Carroll, K.M. et al. 1994. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch. Gen. Psychiatry 51: 177-187.
32. Carroll, K.M. et al. 1994. One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. Arch. Gen. Psychiatry 51: 989-997.
33. Rawson, R.A. et al. 2004. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 99: 708-717.
34. Higgins, S.T. et al. 1994. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch. Gen. Psychiatry 51: 568-576.
35. Roll, J.M. et al. 2006. Contingency management for the treatment of methamphetamine use disorders. Am. J. Psychiatry 163: 1993-1999.
36. Gorelick, D.A., E.L. Gardner & Z.X. Xi. 2004. Agents in development for the management of cocaine abuse. Drugs 64: 1547-1573.
37. Cornish, J.W. et al. 1997. Naltrexone pharmacotherapy for opioid dependent federal probationers. J. Subst. Abuse Treat. 14: 529-534.
38. Rea, F. et al. 2004. A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug Alcohol Depend. 75: 79-88.
39. Rose, J.E. & F.M. Behm. 2004. Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments. Nicotine Tob. Res. 6: 523-532.
40. De Lima, M.S. et al. 2002. Pharmacological treatment of cocaine dependence: a systematic review. Addiction 97: 931-949.
41. Grabowski, J. et al. 2004. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict. Behav. 29: 1439-1464.
42. Newton, T.F. et al. 2001. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res. 102: 227-233.
43. Platt,D.M., J.K.Rowlett&R.D. Spealman. 2002. Behavioral effects of cocaine and dopaminergic strategies for preclinicalmedication development. Psychopharmacology (Berl) 163: 265-282.
44. Grabowski, J. et al. 2000. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J. Clin. Psychopharmacol. 20: 305-310.
45. Grabowski, J. et al. 2004. Agonist-like or antagonistlike treatment for cocaine dependence withmethadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 29: 969-981.
46. Kampman, K.M. et al. 2003. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend. 70: 265-273.
47. Bradberry, C.W. et al. 1993. Cocaine and cocaethylene: microdialysis comparison of brain drug levels and effects on dopamine and serotonin. J. Neurochem. 60: 1429-1435.
48. Kankaanpaa, A. et al. 1998. The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol. Biochem. Behav. 59: 1003-1009.
49. Reith, M.E., M.Y. Li & Q.S. Yan. 1997. Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacology (Berl) 134: 309-317.
50. Rothman, R.B. et al. 2001. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
51. Segal, D.S. & R. Kuczenski. 1997. An escalating dose "binge" model of amphetamine psychosis: behavioral and neurochemical characteristics. J. Neurosci. 17: 2551-2566.
52. Herin, D.V. & J. Grabowski. 2007. Agonist treatment for stimulant abuse and dependence. In Translations of Addiction Science into Practice. P.M. Miller & D.J. Kavanagh, Eds.: 145-167. Elsevier. Amsterdam.
53. Koob,G.F. 1992.Neural mechanisms of drug reinforcement. Ann. N. Y. Acad. Sci. 654: 171-191.
54. Martinez, D. et al. 2007. Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am. J. Psychiatry 164: 622-629.
55. Volkow, N.D. et al. 2001. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am. J. Psychiatry 158: 2015-2021.
56. Volkow, N.D. et al. 1990. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am. J. Psychiatry 147: 719-724.
57. Volkow, N.D. et al. 1997. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386: 830-833.
58. Bubar, M.J. & K.A. Cunningham. 2008. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse. Prog. Brain Res. 172: 319-346.
59. Herin, D.V. et al. 2005. Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of -3,4-methylenedioxymethamphetamine. Psychopharmacology (Berl) 178: 505-513.
60. Walsh, S.L. & K.A. Cunningham. 1997. Serotonergic mechanisms involved in thediscriminative stimulus, reinforcing and subjective effects of cocaine. Psychopharmacology (Berl) 130: 41-58.
61. Covi, L. et al. 1995. Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers. Am. J. Drug Alcohol Abuse 21: 327-344.
62. Grabowski, J. et al. 1995. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. J. Clin. Psychopharmacol. 15: 163-174.
63. Gawin, F.H. et al. 1989. Desipramine facilitation of initial cocaine abstinence. Arch. Gen. Psychiatry 46: 117-121.
64. Kosten, T.R. et al. 1992. Pharmacotherapy for cocaineabusing methadone-maintained patients using amantadine or desipramine. Arch. Gen. Psychiatry 49: 894-898.
65. Rothman, R.B., B.E. Blough & M.H. Baumann. 2008. Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction. Exp. Clin. Psychopharmacol. 16: 458-474.
66. Schuster, C.R. & C.E. Johanson. 1988. Relationship between the discriminative stimulus properties and subjective effects of drugs. Psychopharmacol. Ser. 4: 161-175.
67. Fischman, M.W. & R.W. Foltin. 1998. Cocaine self administration research: implications for rational pharmacotherapy. InCocaineAbuseResearch: Pharmacology, Behavior, and Clinical Applications. S.T. Higgins & J.L. Katz, Eds.: 181-208. Academic Press. San Diego.
68. Comer, S.D. et al. 2008. The role of human drug selfadministration procedures in the development ofmedications. Drug Alcohol Depend. 96: 1-15.
69. Haney, M. 2009. Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. Addict. Biol. 14: 9-21.
70. Haney, M.&R. Spealman. 2008.Controversies in translational research: drug self-administration. Psychopharmacology (Berl) 199: 403-419.
71. Greenhill, L.L. et al. 2002. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J. Am. Acad. Child Adolesc. Psychiatry 41: 26S-49S.
72. Rothman, R.B. & M.H. Baumann. 2003. Monoamine transporters and psychostimulant drugs. Eur. J. Pharmacol. 479: 23-40.
73. Kuczenski, R. & D.S. Segal. 1997. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 68: 2032-2037. (Pubitemid 27176139)
74. Shoblock, J.R. et al. 2003. Neurochemical and behavioral differences between d-methamphetamine and damphetamine in rats. Psychopharmacology (Berl) 165: 359-369.
75. Li, S.M.,B.L.Campbell&J.L.Katz. 2006. Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats discriminating cocaine. J. Pharmacol. Exp. Ther. 317: 1088-1096.
76. Bondareva, T.S., R. Young & R.A. Glennon. 2002. Central stimulants as discriminative stimuli. Asymmetric generalization between ephedrine and Smethamphetamine. Pharmacol. Biochem. Behav. 74: 157-162.
77. Balster, R.L. & C.R. Schuster. 1973. A comparison of d-amphetamine, l-amphetamine, and methamphetamine self-administration in rhesus monkeys. Pharmacol. Biochem. Behav. 1: 67-71.
78. Negus, S.S. & N.K. Mello. 2003. Effects of chronic d-amphetamine treatment on cocaine- and foodmaintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend. 70: 39-52.
79. Peltier, R.L. et al. 1996. Chronic d-amphetamine or methamphetamine produces cross-tolerance to the discriminative and reinforcing stimulus effects of cocaine. J. Pharmacol. Exp. Ther. 277: 212-218.
80. Negus, S.S. 2003. Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with damphetamine and flupenthixol. Neuropsychopharmacology 28: 919-931.
81. Mello, N.K. & S.S. Negus. 2007. Effects of damphetamine and buprenorphine combinations on speedball (cocaineheroin) self-administration by rhesus monkeys. Neuropsychopharmacology 32: 1985-1994.
82. Czoty, P.W. et al. 2004. Drug discrimination in methamphetamine-trained monkeys: effects of monoamine transporter inhibitors. J. Pharmacol. Exp. Ther. 311: 720-727.
83. Bymaster, F.P. et al. 2002. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27: 699-711.
84. Czoty, P.W., A. Makriyannis & J. Bergman. 2004. Methamphetamine discrimination and in vivo microdialysis in squirrelmonkeys. Psychopharmacology (Berl) 175: 170-178.
85. Bergman, J. et al. 1989. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J. Pharmacol. Exp. Ther. 251: 150-155. (Pubitemid 19261957)
86. Thanos, P.K. et al. 2007. Effects of chronic oral methylphenidate on cocaine self-administration and striatal dopamine D2 receptors in rodents. Pharmacol. Biochem. Behav. 87: 426-433.
87. Jasinski, D.R. & R. Kovacevic-Ristanovic. 2000. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin. Neuropharmacol. 23: 149-156.
88. Myrick, H. et al. 2004. Modafinil: preclinical, clinical, and post-marketing surveillance-a review of abuse liability issues. Ann. Clin. Psychiatry 16: 101-109.
89. Ferraro, L. et al. 1997. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 8: 2883-2887.
90. Ferraro, L. et al. 1996. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur. J. Pharmacol. 306: 33-39.
91. Lin, J.S. et al. 1992. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res. 591: 319-326.
92. Madras, B.K. et al. 2006.Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J. Pharmacol. Exp. Ther. 319: 561-569.
93. Deroche-Gamonet, V. et al. 2002. Study of the addictive potential of modafinil in naive and cocaineexperienced rats. Psychopharmacology (Berl) 161: 387-395.
94. Gold, L.H. & R.L. Balster. 1996. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) 126: 286-292.
95. Nieuwstraten, C.E. & L.R. Dolovich. 2001. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression.Ann. Pharmacother. 35: 1608-1613.
96. Wilkes, S. 2008. The use of bupropion SR in cigarette smoking cessation. Int. J. Chron. Obstruct. Pulmon. Dis. 3: 45-53.
97. Nomikos, G.G. et al. 1989. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 2: 273-279.
98. Kleven, M.S., E.W. Anthony &W.L.Woolverton. 1990. Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 254: 312-317.
99. Munzar, P. & S.R. Goldberg. 2000. Dopaminergic involvement in the discriminative-stimulus effects of methamphetamine in rats. Psychopharmacology (Berl) 148: 209-216. (Pubitemid 30104144)
100. Reichel, C.M. et al. 2009. Bupropion attenuates methamphetamine self-administration in adult male rats. Drug Alcohol Depend. 100: 54-62.
101. Collins, S.L. et al. 2006. Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug Alcohol Depend. 82: 158-167.
102. Johanson, C.E., L.H. Lundahl & H. Schubiner. 2007. Effects of oral cocaine on intravenous cocaine discrimination in humans. Exp. Clin. Psychopharmacol. 15: 219-227.
103. Rush, C.R., W.W. Stoops & L.R. Hays. 2009. Cocaine effects during d-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy. Drug Alcohol Depend. 99: 261-271.
104. Walsh, S.L.,K.A.Haberny&G.E. Bigelow. 2000.Modulation of intravenous cocaine effects by chronic oral cocaine in humans. Psychopharmacology (Berl) 150: 361-373.
105. Winhusen, T. et al. 2006.Methylphenidate and cocaine: a placebo-controlled drug interaction study. Pharmacol. Biochem. Behav. 85: 29-38.
106. Rush, C.R. et al. 2002. Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug Alcohol Depend. 67: 311-322.
107. Dackis, C.A. et al. 2003. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend. 70: 29-37.
108. Hart, C.L. et al. 2008. Smoked cocaine selfadministration is decreased by modafinil. Neuropsychopharmacology 33: 761-768.
109. Malcolm, R. et al. 2006.Modafinil and cocaine interactions. Am. J. Drug Alcohol Abuse 32: 577-587.
110. Rush, C.R., S.H. Kollins & P.J. Pazzaglia. 1998. Discriminative- stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in damphetamine- trained humans. Exp. Clin. Psychopharmacol. 6: 32-44.
111. Oliveto, A. et al. 2001. Effects of cocaine prior to and during bupropion maintenance in cocaineabusing volunteers. Drug Alcohol Depend. 63: 155-167.
112. Newton, T.F. et al. 2006. Bupropion reduces methamphetamine-induced subjective effects and cueinduced craving. Neuropsychopharmacology 31: 1537-1544.
113. Amato, L. et al. 2007. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev. CD006306.
114. Minozzi, S. et al. 2008. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev. CD006754.
115. Shearer, J. & L.R. Gowing. 2004. Pharmacotherapies for problematic psychostimulant use: a review of current research. Drug Alcohol Rev. 23: 203-211.
116. Rothman, R.B. et al. 2005. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J. Pharmacol. Exp. Ther. 313: 1361-1369.
117. Llosa, T. 2007.Handbook on Oral Cocaine in Addictions. Coca Medica. Lima, Peru.
118. Mitcheson, M. et al. 1976. Treatment of methylamphetamine users during the 1976 epidemic. In Drugs and Drug Dependence. G. Edwards, M.A.H. Russell & M.Macafferty, Eds.: 155-162. Saxon House Publishers. London.
119. Mooney, M.E. et al. 2008. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug AlcoholDepend. 101: 34-41.
120. Sherman, J.P. 1990. Dexamphetamine for "speed" addiction. Med. J. Aust. 153: 306.
121. Fleming, P.M. & D. Roberts. 1994. Is the prescription of amphetamine justified as a harmreductionmeasure? J. R. Soc. Health 114: 127-131.
122. Pates, R.C., N. Coombs & N. Ford. 1996. A pilot programme in prescribing dexamphetamine for amphetamine users. J. Subst. Misuse . Nurs. Health Soc. Care 1: 80-84.
123. McBride, A.J. et al. 1997. Amphetamine prescribing as a harmreduction measure: a preliminary study. Addict. Res. 5: 95-112.
124. Merrill, J. & V.A. Tetlow. 1998. Prescribing for amphetamine users: evaluation of a dexamphetamine substitution programme. Presented at Beyond Oral Methadone: Expanded Pharmacotherapies for the Treatment of Drug Dependence, New York.
125. Klee,H. et al. 2001. The role of substitute therapy in the treatment of problem amphetamine use. Drug Alcohol Rev. 20: 417-429.
126. Grabowski, J. et al. 2001. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J. Clin. Psychopharmacol. 21: 522-526.
127. Charnaud, B. & V. Griffiths. 1998. Levels of intravenous drug misuse among clients prescribed oral dexamphetamine or oral methadone: a comparison. Drug Alcohol Depend. 52: 79-84.
128. White, R. 2000. Dexamphetamine substitution in the treatment of amphetamine abuse: an initial investigation. Addiction 95: 229-238.
129. Carnwath, T., T. Garvey & M. Holland. 2002. The prescription of dexamphetamine to patients with schizophrenia and amphetamine dependence. J. Psychopharmacol. 16: 373-377.
130. Shearer, J. et al. 2001. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction 96: 1289-1296.
131. Bisaga,A. et al. 2005.Utility of lead-in period in cocaine dependence pharmacotherapy trials. Drug Alcohol Depend. 77(1): 7-11.
132. Shearer, J. et al. 2003. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 98: 1137-1141.
133. Condelli, W.S. et al. 1991. Cocaine use by clients in methadone programs: significance, scope, and behavioral interventions. J. Subst. Abuse Treat. 8: 203-212.
134. Strug, D.L. et al. 1985. Patterns of cocaine use among methadone clients. Int. J. Addict. 20: 1163-1175.
135. Galloway, G.P. et al. 2009. Dextroamphetamine as a treatment for methamphetamine dependence. College on Problems of Dependence Annual Meeting, Reno/Sparks, Nevada, June 20-25.
136. Khantzian, E.J. et al. 1984. Methylphenidate (Ritalin) treatment of cocaine dependence-a preliminary report. J. Subst. Abuse Treat. 1: 107-112.
137. Khantzian, E.J. 1985. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am. J. Psychiatry 14: 1259-1264.
138. Gawin, F., C. Riordan & H. Kleber. 1985. Methylphenidate treatment of cocaine abusers without attention deficit disorder: a negative report. Am. J. Drug Alcohol Abuse 11: 193-197.
139. Grabowski, J. et al. 1997. Replacement medication for cocaine dependence: methylphenidate. J. Clin. Psychopharmacol. 17: 485-488.
140. Levin, F.R. et al. 1998. Methylphenidate treatment for cocaine abusers with adult attentiondeficit/ hyperactivity disorder: a pilot study. J. Clin. Psychiatry 59: 300-305.
141. Levin, F.R. et al. 2007. Treatment of cocaine dependent treatment seekerswith adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 87: 20-29.
142. Schubiner, H. et al. 2002. Double-blind placebocontrolled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp. Clin. Psychopharmacol. 10: 286-294.
143. Tiihonen, J. et al. 2007. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am. J. Psychiatry 164: 160-162.
144. Malcolm, R. et al. 2002. Clinical applications of modafinil in stimulant abusers: low abuse potential. Am. J. Addict. 11: 247-249.
145. Lindsay, S.E., G.A. Gudelsky & P.C. Heaton. 2006. Use of modafinil for the treatment of attention deficit/hyperactivity disorder. Ann. Pharmacother. 40: 1829-1833.
146. Camacho, A. & M.B. Stein. 2002. Modafinil for social phobia and amphetamine dependence. Am. J. Psychiatry 159: 1947-1948.
147. Dackis, C. & C. O'Brien. 2003. Glutamatergic agents for cocaine dependence. Ann. N. Y. Acad. Sci. 1003: 328-345.
148. Dackis, C.A. et al. 2005. A double-blind, placebocontrolled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30: 205-211.
149. McGregor, C. et al. 2008. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. J. Subst. Abuse Treat. 35: 334-342.
150. Shearer, J. et al. 2009. A double-blind, placebocontrolled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction 104: 224-233.
151. McElhiney, M.C. et al. 2009. Provigil (modafinil) plus cognitive behavioral therapy formethamphetamine use in HIV gay men: a pilot study. Am. J. Drug Alcohol Abuse 35: 34-37.
152. Anderson, A.L. et al. 2009.Modafinil for the treatment of cocaine dependence. Drug AlcoholDepend. 104: 133-139.
153. Kampman, K.M. 2008. The search for medications to treat stimulant dependence. Addict. Sci. Clin. Pract. 4: 28-35.
154. Elkashef, A.M. et al. 2008. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 33: 1162-1170.
155. Mooney, M.E. et al. 2007. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend. 88: 214-223.
156. Schmitz, J.M. et al. 2008. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend. 94: 142-150.
157. Stine, S.M., B. Burns & T. Kosten. 1991. Methadone dose for cocaine abuse. Am. J. Psychiatry 148: 1268.
158. Benedict, R.H. et al. 2008. Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. J. Neurol. 255: 848-852.
159. Herin, D.V. et al. 2008. Sequential agonist strategies for cocaine dependence: bayesian analysis. Presented at College on Problems of Drug Dependence Annual Meeting, San Juan, Puerto Rico, June 14-19.
160. Moukaddam, N. et al. 2008. Comparison of 3 L- [alpha]-acetyl-methadol (LAAM) maintenance strategies for heroin dependence. Addict. Disord. Their Treat. E-pub ahead of print doi: 10.1097/ADT.0b013 e3181848b04.
161. Ermer, J. et al. 2009. Pharmacokinetics of lisdexamfetamine dimesylate following intranasal administration. College on Problems of Dependence Annual Meeting, Reno/Sparks, Nevada, June 20-25.
162. Jasinski, D.R. & D. Krishnan. 2006. Abuse liability of intravenous l-lysine-d-amphetamine (NRP 104). Presented at College on Problems of Drug Dependence, Scottsdale, AZ, June 17-22.
163. Biederman, J. et al. 2007. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol. Psychiatry 62: 970-976.
164. Jasinski, D.R. & D. Krishnan. 2006. A double-blind, randomized, placebo- and active-controlled, 6-period crossover study to evaluate the likability, safety, and abuse potential of lisdexamfetamine dimesylate in adult stimulant abusers. Presented at U.S. Psychiatric and Mental Health Congress, New Orleans, LA, November 15-19.
165. Jasinski, D.R. & D. Krishnan. 2006. Pharmacokinetics of lisdexamfetamine vs. d-amphetamine in adults with a history of stimulant abuse. Presented at 58th Institute on Psychiatric Services, New York, October 5-8.
166. Buydens-Branchey, L. et al. 1999. Serotonergic function in cocaine addicts: prolactin responses to sequential d,l-fenfluramine challenges. Biol. Psychiatry 45: 1300-1306.
167. McDougle, C.J. et al. 1994. Noradrenergic dysregulation during discontinuation of cocaine use in addicts. Arch. Gen. Psychiatry 51: 713-719.
168. Glatz, A.C. et al. 2002. Inhibition of cocaine selfadministration by fluoxetine or d-fenfluramine combined with phentermine. Pharmacol. Biochem. Behav. 71: 197-204.
169. Kampman, K.M. et al. 2000. The combination of phentermine and fenfluramine reduced cocaine withdrawal symptoms in an open trial. J. Subst. Abuse Treat. 19: 77-79.
170. Negus, S.S. et al. 2009. Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, phenmetrazine, and 4-benzylpiperidine. J. Pharmacol. Exp. Ther. 329(1): 272-281.
171. Rothman, R.B. et al. 2002. Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur. J. Pharmacol. 447: 51-57.